HIV molecular immunology database

 

Search the Epitope Variant and Escape Mutation Database

Help


Found 1 matching record:

Displaying record number 59102

HXB2 Location  gp160(168-176)   gp160 Epitope Map
View variants at this location
Epitope KMQKEYALL   Epitope Alignment
Variants
KkQKvhALf   HLA association; observed variant; subtype-specific susceptible form
KkQqvYALf   HLA association; diminished HLA binding or increased off-rate; observed variant; subtype-specific susceptible form
KqrKvqALf   HLA association; diminished HLA binding or increased off-rate; observed variant; subtype-specific susceptible form
KkQKfYALf   diminished HLA binding or increased off-rate; non-susceptible form; observed variant; subtype-specific susceptible form
KrQqvhALf   diminished HLA binding or increased off-rate; non-susceptible form; observed variant; subtype-specific susceptible form
KqQKvYALf   diminished HLA binding or increased off-rate; non-susceptible form; observed variant; subtype-specific susceptible form
rkQqiSALf   HLA association; diminished HLA binding or increased off-rate; observed variant; subtype-specific susceptible form
KqQnfYALf   HLA association; diminished HLA binding or increased off-rate; observed variant; subtype-specific susceptible form
KqQqihALf   HLA association; diminished HLA binding or increased off-rate; observed variant; subtype-specific susceptible form
Epitope Name KL9, 168-KMQKEYALL
Species (MHC/HLA human(A*02)

Variant Details

Showing all: 9 variant(s).


Variant ID.  3280
Epitope Seq.  KMQKEYALL
Variant Seq.  KkQKvhALf
Mutations M/K E/V Y/H L/F
Epitope Location M2K E5V Y6H L9F
HXB2 Location M169K E172V Y173H L176F
Mutation Type A: HLA association
OV: observed variant
SSF: subtype-specific susceptible form
Epitope Subtype B
Variant Subtype CRF01_AE
Method CD8 T-cell Elispot - IFNy, Peptide titration
Note Subtype CRF01_AE-specific variant KMQKvhALf, from either strains 92TH023 or A244, bound HLA-A*0203 with IC50 = 2281 nM, but did not bind HLAs -A*0201 or -A*0207 appreciably.


Variant ID.  3282
Epitope Seq.  KMQKEYALL
Variant Seq.  KkQqvYALf
Mutations M/K K/Q E/V L/F
Epitope Location M2K K4Q E5V L9F
HXB2 Location M169K K171Q E172V L176F
Mutation Type A: HLA association
DHB: diminished HLA binding or increased off-rate
OV: observed variant
SSF: subtype-specific susceptible form
Epitope Subtype B
Variant Subtype CRF01_AE
Method CD8 T-cell Elispot - IFNy, Peptide titration
Note Subtype CRF01_AE-specific variant KkQqvYALf, from either strains 92TH023 or A244, bound HLA-A*0203 with IC50 = 25294 nM, but did not bind HLAs -A*0201 or -A*0207 appreciably. This variant was isolated from both RV144 vaccinated and -placebo CRF01_AE-infected recipients.


Variant ID.  3283
Epitope Seq.  KMQKEYALL
Variant Seq.  KqrKvqALf
Mutations M/Q Q/R E/V Y/Q L/F
Epitope Location M2Q Q3R E5V Y6Q L9F
HXB2 Location M169Q Q170R E172V Y173Q L176F
Mutation Type A: HLA association
DHB: diminished HLA binding or increased off-rate
OV: observed variant
SSF: subtype-specific susceptible form
Epitope Subtype B
Variant Subtype CRF01_AE
Method CD8 T-cell Elispot - IFNy, Peptide titration
Note Subtype CRF01_AE-specific variant KqrKvqALf, from either strains 92TH023 or A244, bound HLA-A*0203 with IC50 = 25667 nM, but did not bind HLAs -A*0201 or -A*0207 appreciably. This variant was isolated from an RV144-vaccinated CRF01_AE-infected recipient.


Variant ID.  3284
Epitope Seq.  KMQKEYALL
Variant Seq.  KkQKfYALf
Mutations M/K E/F L/F
Epitope Location M2K E5F L9F
HXB2 Location M169K E172F L176F
Mutation Type DHB: diminished HLA binding or increased off-rate
NSF: non-susceptible form
OV: observed variant
SSF: subtype-specific susceptible form
Epitope Subtype B
Variant Subtype CRF01_AE
Method CD8 T-cell Elispot - IFNy, Peptide titration
Note Subtype CRF01_AE-specific variant KkQKfYALf, from either strains 92TH023 or A244, did not bind tested HLAs -A*0203 -A*0201 or -A*0207 appreciably. This variant was isolated from both RV144-vaccinated and -placebo CRF01_AE-infected recipients.


Variant ID.  3285
Epitope Seq.  KMQKEYALL
Variant Seq.  KrQqvhALf
Mutations M/R K/Q E/V Y/H L/F
Epitope Location M2R K4Q E5V Y6H L9F
HXB2 Location M169R K171Q E172V Y173H L176F
Mutation Type DHB: diminished HLA binding or increased off-rate
NSF: non-susceptible form
OV: observed variant
SSF: subtype-specific susceptible form
Epitope Subtype B
Variant Subtype CRF01_AE
Method CD8 T-cell Elispot - IFNy, Peptide titration
Note Subtype CRF01_AE-specific variant KrQqvhALf, from either strains 92TH023 or A244, did not bind tested HLAs -A*0203 -A*0201 or -A*0207 appreciably. This variant was isolated from an RV144-vaccinated CRF01_AE-infected recipient.


Variant ID.  3286
Epitope Seq.  KMQKEYALL
Variant Seq.  KqQKvYALf
Mutations M/Q E/V L/F
Epitope Location M2Q E5V L9F
HXB2 Location M169Q E172V L176F
Mutation Type DHB: diminished HLA binding or increased off-rate
NSF: non-susceptible form
OV: observed variant
SSF: subtype-specific susceptible form
Epitope Subtype B
Variant Subtype CRF01_AE
Method CD8 T-cell Elispot - IFNy, Peptide titration
Note Subtype CRF01_AE-specific variant KqQKvYALf, from either strains 92TH023 or A244, did not bind tested HLAs -A*0203 -A*0201 or -A*0207 appreciably. This variant was isolated from both RV144-vaccinated and -placebo CRF01_AE-infected recipients.


Variant ID.  3288
Epitope Seq.  KMQKEYALL
Variant Seq.  rkQqiSALf
Mutations K/R M/K K/Q E/I Y/S L/F
Epitope Location K1R M2K K4Q E5I Y6S L9F
HXB2 Location K168R M169K K171Q E172I Y173S L176F
Mutation Type A: HLA association
DHB: diminished HLA binding or increased off-rate
OV: observed variant
SSF: subtype-specific susceptible form
Epitope Subtype B
Variant Subtype CRF01_AE
Method CD8 T-cell Elispot - IFNy, Peptide titration
Note Subtype CRF01_AE-specific variant rkQqiSALf, from either strains 92TH023 or A244, bound HLA-A*0201 with IC50 = 34021 nM, but did not bind HLAs -A*0203 or -A*0207 appreciably. This variant was isolated from an RV144-vaccinated CRF01_AE-infected recipient.


Variant ID.  3289
Epitope Seq.  KMQKEYALL
Variant Seq.  KqQnfYALf
Mutations M/Q K/N E/F L/F
Epitope Location M2Q K4N E5F L9F
HXB2 Location M169Q K171N E172F L176F
Mutation Type A: HLA association
DHB: diminished HLA binding or increased off-rate
OV: observed variant
SSF: subtype-specific susceptible form
Epitope Subtype B
Variant Subtype CRF01_AE
Method CD8 T-cell Elispot - IFNy, Peptide titration
Note Subtype CRF01_AE-specific variant KqQnfYALf, from either strains 92TH023 or A244, bound HLAs -A*0201 and -A*0207 with IC50 = 1768 nM and 36940 nM respectively, but did not bind HLA -A*0203 appreciably. This variant was isolated from an RV144-vaccinated CRF01_AE-infected recipient.


Variant ID.  3290
Epitope Seq.  KMQKEYALL
Variant Seq.  KqQqihALf
Mutations M/Q K/Q E/I Y/H L/F
Epitope Location M2Q K4Q E5I Y6H L9F
HXB2 Location M169Q K171Q E172I Y173H L176F
Mutation Type A: HLA association
DHB: diminished HLA binding or increased off-rate
OV: observed variant
SSF: subtype-specific susceptible form
Epitope Subtype B
Variant Subtype CRF01_AE
Method CD8 T-cell Elispot - IFNy, Peptide titration
Note Subtype CRF01_AE-specific variant KqQqihALf, from either strains 92TH023 or A244, bound HLAs -A*0201 and -A*0207 with IC50 = 16306 nM and 37102 nM respectively, but did not bind HLA -A*0203 appreciably. This variant was isolated from an RV144-placebo CRF01_AE-infected recipient.

References

Gartland2014 Andrew J. Gartland, Sue Li, John McNevin, Georgia D. Tomaras, Raphael Gottardo, Holly Janes, Youyi Fong, Daryl Morris, Daniel E. Geraghty, Gustavo H. Kijak, Paul T. Edlefsen, Nicole Frahm, Brendan B. Larsen, Sodsai Tovanabutra, Eric Sanders-Buell, Allan C. deCamp, Craig A. Magaret, Hasan Ahmed, Jodie P. Goodridge, Lennie Chen, Philip Konopa, Snehal Nariya, Julia N. Stoddard, Kim Wong, Hong Zhao, Wenjie Deng, Brandon S. Maust, Meera Bose, Shana Howell, Adam Bates, Michelle Lazzaro, Annemarie O'Sullivan, Esther Lei, Andrea Bradfield, Grace Ibitamuno, Vatcharain Assawadarachai, Robert J. O'Connell, Mark S. deSouza, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Merlin L. Robb, John Sidney, Alessandro Sette, Susan Zolla-Pazner, David Montefiori, M. Juliana McElrath, James I. Mullins, Jerome H. Kim, Peter B. Gilbert, and Tomer Hertz. Analysis of HLA A*02 Association with Vaccine Efficacy in The RV144 HIV-1 Vaccine Trial. J. Virol., 88(15):8242-8255, Aug 2014. PubMed ID: 24829343. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health